Julian Taugner

Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients

Julian Taugner, Lukas Käsmann, Chukwuka Eze et al. · Investigational New Drugs · 2021 · 42 citations · Full text

Medicine, Oncology, Radiation Oncology +16

Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy

K. Gennen, Lukas Käsmann, Julian Taugner et al. · Radiation Oncology · 2020 · 41 citations · Full text

Life Sciences, Immunology, Oncology +17

Pattern-of-failure and salvage treatment analysis after chemoradiotherapy for inoperable stage III non-small cell lung cancer

Julian Taugner, Chukwuka Eze, Lukas Käsmann et al. · Radiation Oncology · 2020 · 29 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Durvalumab after Chemoradiotherapy for PD-L1 Expressing Inoperable Stage III NSCLC Leads to Significant Improvement of Local-Regional Control and Overall Survival in the Real-World Setting

Julian Taugner, Lukas Käsmann, Chukwuka Eze et al. · Cancers · 2021 · 29 citations · Full text

Medicine, Oncology, Radiation Oncology +12

Performance Status and Its Changes Predict Outcome for Patients With Inoperable Stage III NSCLC Undergoing Multimodal Treatment

Lukas Käsmann, Julian Taugner, Chukwuka Eze et al. · Anticancer Research · 2019 · 26 citations · Full text

Medicine, Oncology, Radiation Oncology +17